NCT06840990

Cross-linked CMC and Silk Proteins in Corneal Re-epithelization

Ophthalmic Solution in Corneal Re-epithelization

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: D&V FARMA srl · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Data analyses and revision of the corneal re-epithelization in patients who underwent either PRK (Photorefractive Keratectomy), CXL (Corneal Cross-Linking), PTK (phototherapeutic keratectomy), or experienced a corneal abrasion. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their wound healing properties in the ophtalmic field. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

Conditions

• Corneal Epithelial Wound Healing

Interventions

Type	Name	Description
DEVICE	CXC-SP	Standard therapy plus sterile Isotonic ophthalmic solution based on CX-CMC and silk protein, istilled six time a day until complete healing.
DEVICE	CTRL	Standard therapy plus sterile ophtalmic isotonic solution for six time a day until complete healing.

Timeline

• Start date: 2023-01-01
• Primary completion: 2024-05-01
• Completion: 2024-06-01
• First posted: 2025-02-21
• Last updated: 2025-03-07

Locations

1 site across 1 country: Italy